A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

Inclusion criteria: * Patients with a first recorded secukinumab prescription between 01 January 2021 and 31 December 2023. * Patients aged ≥18 years at index date. * Patients with no prior secukinumab exposure in available EMR history. * Secukinumab must be patient's first-, second-, or third-line biologic therapy for psoriasis/psoriatic arthritis (PsA). * Patients with documented administration per Summary of Product Characteristics dosing recommendations (SmPC). * Patients with confirmed plaque psoriasis with or without PsA. * Patients with at least one cardiometabolic risk factor. * Patients with a confirmed MASLD diagnosis. * Patients with baseline laboratory data available. Exclusion criteria: * Patients with evidence of MASLD absence. * Patients with malignant liver disease. * Patients with a history of liver transplantation. * Patients with alcohol use disorder. * Patients with other chronic liver diseases. * Patients with diseases or treatments which cause thrombocytopenia. * Patients with decompensated cirrhosis. Other protocol-defined inclusion/exclusion criteria may apply.